Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1991 Sep;35(9):1721–1725. doi: 10.1128/aac.35.9.1721

Treatment of murine cryptococcal meningitis with an SCH 39304-amphotericin B combination.

M M Albert 1, J R Graybill 1, M G Rinaldi 1
PMCID: PMC245257  PMID: 1952837

Abstract

Cryptococcal meningitis was induced in BALB/c mice by intracerebral infection with Cryptococcus neoformans. Drug therapy was initiated 1 day later, with mice receiving amphotericin B (AMB), SCH 39304, combination therapy, or no drug therapy (controls). Most, but not all, combinations showed additive benefits, significantly prolonging survival and reducing organism counts in tissues compared with those in controls and groups which received the drugs independently. Optimum protection was obtained when a single dose of 10 mg of AMB per kg of body weight was combined with a fairly narrow SCH 39304 dose range. AMB antagonism did not occur with any regimen tested. AMB-azole combinations may be reasonable alternatives for patients who fail standard cryptococcosis therapeutic regimens.

Full text

PDF
1721

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Armstrong D. Life-threatening opportunistic fungal infection in patients with the acquired immunodeficiency syndrome. Ann N Y Acad Sci. 1988;544:443–450. doi: 10.1111/j.1749-6632.1988.tb40442.x. [DOI] [PubMed] [Google Scholar]
  2. Dismukes W. E. Cryptococcal meningitis in patients with AIDS. J Infect Dis. 1988 Apr;157(4):624–628. doi: 10.1093/infdis/157.4.624. [DOI] [PubMed] [Google Scholar]
  3. Galgiant J. N., Stevens D. A. Turbidimetric studies of growth inhibition of yeasts with three drugs: inquiry into inoculum-dependent susceptibility testing, time of onset of drug effect, and implications for current and newer methods. Antimicrob Agents Chemother. 1978 Feb;13(2):249–254. doi: 10.1128/aac.13.2.249. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Graybill J. R., Williams D. M., Van Cutsem E., Drutz D. J. Combination therapy of experimental histoplasmosis and cryptococcosis with amphotericin B and ketoconazole. Rev Infect Dis. 1980 Jul-Aug;2(4):551–558. doi: 10.1093/clinids/2.4.551. [DOI] [PubMed] [Google Scholar]
  5. Gruda I., Nadeau P., Brajtburg J., Medoff G. Application of differential spectra in the ultraviolet-visible region to study the formation of amphotericin B-sterol complexes. Biochim Biophys Acta. 1980 Nov 4;602(2):260–268. doi: 10.1016/0005-2736(80)90309-0. [DOI] [PubMed] [Google Scholar]
  6. Harris S. C., Wallace J. E., Foulds G., Rinaldi M. G. Assay of fluconazole by megabore capillary gas-liquid chromatography with nitrogen-selective detection. Antimicrob Agents Chemother. 1989 May;33(5):714–716. doi: 10.1128/aac.33.5.714. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Kotler-Brajtburg J., Medoff G., Kobayashi G. S., Schlessinger D. Sensitivity to amphotericin B and the cholesterol: phospholipid molar ratios of 3T3, L, BHK and HeLa cells. Biochem Pharmacol. 1977 Apr 15;26(8):705–710. doi: 10.1016/0006-2952(77)90212-x. [DOI] [PubMed] [Google Scholar]
  8. Kovacs J. A., Kovacs A. A., Polis M., Wright W. C., Gill V. J., Tuazon C. U., Gelmann E. P., Lane H. C., Longfield R., Overturf G. Cryptococcosis in the acquired immunodeficiency syndrome. Ann Intern Med. 1985 Oct;103(4):533–538. doi: 10.7326/0003-4819-103-4-533. [DOI] [PubMed] [Google Scholar]
  9. Lopez-Berestein G., Fainstein V., Hopfer R., Mehta K., Sullivan M. P., Keating M., Rosenblum M. G., Mehta R., Luna M., Hersh E. M. Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. J Infect Dis. 1985 Apr;151(4):704–710. doi: 10.1093/infdis/151.4.704. [DOI] [PubMed] [Google Scholar]
  10. Lopez-Berestein G. Liposomes as carriers of antifungal drugs. Ann N Y Acad Sci. 1988;544:590–597. doi: 10.1111/j.1749-6632.1988.tb40459.x. [DOI] [PubMed] [Google Scholar]
  11. Medoff G. Controversial areas in antifungal chemotherapy: short-course and combination therapy with amphotericin B. Rev Infect Dis. 1987 Mar-Apr;9(2):403–407. doi: 10.1093/clinids/9.2.403. [DOI] [PubMed] [Google Scholar]
  12. Medoff G., Kobayashi G. S. Strategies in the treatment of systemic fungal infections. N Engl J Med. 1980 Jan 17;302(3):145–155. doi: 10.1056/NEJM198001173020304. [DOI] [PubMed] [Google Scholar]
  13. Meunier F., Sculier J. P., Coune A., Brassinne C., Heyman C., Laduron C., Collette N., Hollaert C., Bron D., Klastersky J. Amphotericin B encapsulated in liposomes administered to cancer patients. Ann N Y Acad Sci. 1988;544:598–610. doi: 10.1111/j.1749-6632.1988.tb40460.x. [DOI] [PubMed] [Google Scholar]
  14. Polak A., Scholer H. J., Wall M. Combination therapy of experimental candidiasis, cryptococcosis and aspergillosis in mice. Chemotherapy. 1982;28(6):461–479. doi: 10.1159/000238138. [DOI] [PubMed] [Google Scholar]
  15. Raviglione M. C., Battan R., Pablos-Mendez A., Aceves-Casillas P., Mullen M. P., Taranta A. Infections associated with Hickman catheters in patients with acquired immunodeficiency syndrome. Am J Med. 1989 Jun;86(6 Pt 2):780–786. doi: 10.1016/0002-9343(89)90473-7. [DOI] [PubMed] [Google Scholar]
  16. Restrepo B. I., Ahrens J., Graybill J. R. Efficacy of SCH39304 in murine cryptococcosis. Antimicrob Agents Chemother. 1989 Aug;33(8):1242–1246. doi: 10.1128/aac.33.8.1242. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Saag M. S., Dismukes W. E. Azole antifungal agents: emphasis on new triazoles. Antimicrob Agents Chemother. 1988 Jan;32(1):1–8. doi: 10.1128/aac.32.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Schaffner A., Frick P. G. The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis. J Infect Dis. 1985 May;151(5):902–910. doi: 10.1093/infdis/151.5.902. [DOI] [PubMed] [Google Scholar]
  19. Sokol-Anderson M. L., Brajtburg J., Medoff G. Amphotericin B-induced oxidative damage and killing of Candida albicans. J Infect Dis. 1986 Jul;154(1):76–83. doi: 10.1093/infdis/154.1.76. [DOI] [PubMed] [Google Scholar]
  20. Sokol-Anderson M. L., Brajtburg J., Medoff G. Sensitivity of Candida albicans to amphotericin B administered as single or fractionated doses. Antimicrob Agents Chemother. 1986 Apr;29(4):701–702. doi: 10.1128/aac.29.4.701. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Stamm A. M., Diasio R. B., Dismukes W. E., Shadomy S., Cloud G. A., Bowles C. A., Karam G. H., Espinel-Ingroff A. Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am J Med. 1987 Aug;83(2):236–242. doi: 10.1016/0002-9343(87)90691-7. [DOI] [PubMed] [Google Scholar]
  22. Sugar A. M., Stern J. J., Dupont B. Overview: treatment of cryptococcal meningitis. Rev Infect Dis. 1990 Mar-Apr;12 (Suppl 3):S338–S348. doi: 10.1093/clinids/12.supplement_3.s338. [DOI] [PubMed] [Google Scholar]
  23. Van den Bossche H., Willemsens G., Cools W., Marichal P., Lauwers W. Hypothesis on the molecular basis of the antifungal activity of N-substituted imidazoles and triazoles. Biochem Soc Trans. 1983 Dec;11(6):665–667. doi: 10.1042/bst0110665. [DOI] [PubMed] [Google Scholar]
  24. Vanden Bossche H. Biochemical targets for antifungal azole derivatives: hypothesis on the mode of action. Curr Top Med Mycol. 1985;1:313–351. doi: 10.1007/978-1-4613-9547-8_12. [DOI] [PubMed] [Google Scholar]
  25. Vertut-Croquin A., Bolard J., Chabbert M., Gary-Bobo C. Differences in the interaction of the polyene antibiotic amphotericin B with cholesterol- or ergosterol-containing phospholipid vesicles. A circular dichroism and permeability study. Biochemistry. 1983 Jun 7;22(12):2939–2944. doi: 10.1021/bi00281a024. [DOI] [PubMed] [Google Scholar]
  26. Walsh T. J., Lester-McCully C., Rinaldi M. G., Wallace J. E., Balis F. M., Lee J. W., Pizzo P. A., Poplack D. G. Penetration of SCH-39304, a new antifungal triazole, into cerebrospinal fluid of primates. Antimicrob Agents Chemother. 1990 Jun;34(6):1281–1284. doi: 10.1128/aac.34.6.1281. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Washington J. A., 2nd Discrepancies between in vitro activity of and in vivo response to antimicrobial agents. Diagn Microbiol Infect Dis. 1983 Mar;1(1):25–31. doi: 10.1016/0732-8893(83)90029-9. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES